Indomethacin vs Diclofenac for Preventing PEP
Recruiting
N/A
Interventional Study
ERCP
Pancreatitis
Non-steroidal Anti-inflammatory (NSAID)
Indomethacin
Diclofenac
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 90
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 4,050 (estimated)
- Sponsor
- Air Force Military Medical University, China · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Pancreatitis is the most common and serious complication following post-endoscopic retrograde cholangiopancreatography (ERCP) and is associated with occasional mortality, extended hospital stays, and increased healthcare expenses. Preprocedural administration of rectal non-steroidal anti-inflammatory drugs (NSAIDs) was demonstrated to be an effective and convenient strategy for post-ERCP pancreati…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* 18-90 years old patients with native papilla who planned to undergo ERCP
Exclusion Criteria:
* Previous biliary sphincterotomy and papillary large balloon dilation
* Planned for placements of pancreatic duct stents (eg. pancreatic duct strictures, planned ampullectomy)
* All…
Contacts